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Abstract: In 2 double-blinded Phase 3 trials, 1733 antiretroviral-
naive participants were randomized to tenofovir alafenamide (TAF),
a tenofovir prodrug versus tenofovir disoproxil fumarate (TDF), each
coformulated with elvitegravir/cobicistat/emtricitabine (E/C/F). At
96 weeks, 86.6% in the TAF arm and 85.2% in the TDF arm had
HIV-1 RNA ,50 c/mL [difference 1.5%; (95% CI: 21.8% to
4.8%)]. With TAF, there are smaller declines in bone mineral density
and more favorable changes in proteinuria, albuminuria, and tubular
proteinuria, and no cases of proximal tubulopathy compared with 2
for TDF. These longer-term data support E/C/F/TAF as a safe, well-
tolerated, and durable regimen for initial HIV-1 treatment.
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INTRODUCTION
Nucleoside and nucleotide reverse transcriptase inhib-
itors (NRTIs) have been included in all regimens recom-
mended by each major HIV treatment guideline panel.1–4
Although newer agents in this antiretroviral class are much
better tolerated than the NRTIs used earlier in the epidemic,
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there remain concerns for the potential for longer-term
toxicity of the current NRTIs.5
Tenofovir disoproxil fumarate (TDF) is a potent and
generally well-tolerated nucleotide analog, which has been
associated with an increased risk of nephrotoxicity6–8 and
greater reductions in bone mineral density (BMD)9–11 com-
pared with other NRTIs. As a prodrug, TDF is metabolized to
tenofovir (TFV), which, in turn, is metabolized intracellularly
to its active metabolite, TFV diphosphate (TFV-DP). Higher
circulating plasma levels of TFV have been correlated with
both renal and bone adverse effects of TDF.12 Tenofovir
alafenamide (TAF) is also an oral prodrug of TFV, but is much
more stable in plasma as compared with TDF, allowing for
a ten-fold lowering of dose. These characteristics result in a
substantial reduction (90%) in circulating TFV exposure, while
achieving an approximately 4-fold increase in intracellular
levels of TFV-DP in peripheral blood mononuclear cells.13
GS-US-292-0104 and GS-US-292-0111 (ClinicalTrials.
gov, numbers NCT01780506 and NCT01797445) are 2 large
randomized, international, double-blind, placebo-controlled
trials comparing initiation of HIV therapy with TAF versus
TDF in those also receiving elvitegravir (EVG, E), cobicistat
(C), and emtricitabine (FTC, F) in single-tablet formulations.
After 48 weeks, high rates of suppression of viremia below
50 copies per milliliter were observed in both study arms (TAF,
92% and TDF, 90%) and TAF met the primary objective of
noninferior efficacy compared with TDF, defined as the
proportion of participants who had HIV-1 RNA ,50 copies
per milliliter using the US Food and Drug Administration
(FDA) snapshot algorithm.14 Moreover, those assigned TAF
had significantly reduced bone demineralization in the lumbar
spine and hip; and a significantly smaller mean change in serum
creatinine; significantly lower rates of total proteinuria, albu-
minuria, and proximal tubular proteinuria compared with those
assigned TDF. In contrast, those assigned TDF experienced
greater declines in lipids compared with those on TAF, with
lower total, low density lipoprotein (LDL), and high density
lipoprotein (HDL) fractions, as expected given the known off-
target lipid effect of TDF in HIV-infected and HIV-uninfected
individuals.15,16 These improvements in bone and renal end-
points as well as the lack of off-target lipid effect are
presumably driven by markedly lower plasma levels of TFV.
We now present the safety and efficacy data collected from
participants in these trials during the second year of on-
study follow-up.
METHODS
Study Design and Participants
The design and inclusion criteria of the trials have been
previously described.14 Briefly, antiretroviral-naive adults
(aged $18 years) with HIV-1 RNA at least 1000 copies per
milliliter, estimated glomerular filtration (creatinine clearance,
Cockcroft–Gault) rate of at least 50 mL/min, and genotypic
sensitivity to EVG, FTC, and TDF were randomized 1:1 to
receive once daily administration of TAF 10 mg versus TDF
300 mg, both coformulated with EVG 150 mg, cobicistat
150 mg, and emtricitabine 200 mg (E/C/F) with a double-
blind, double-dummy design. Randomization was stratified by
HIV-1 RNA (#100,000 copies per milliliter, .100,000 to
#400,000 copies per milliliter, or .400,000 copies per
milliliter), CD4 count (,50 cells per microliter, 50 to 199
cells per microliter, or $200 cells per microliter), and region
(United States, or non-United States) at screening.
Randomized participants were seen at screening, base-
line, and at weeks 2, 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, and
96. Laboratory tests included hematological analysis, serum
chemistry tests, fasting lipid parameters, CD4 counts, meas-
ures of renal function (estimated creatinine clearance by
Cockcroft–Gault, urine protein to creatinine ratio, urine
albumin to creatinine ratio, retinol-binding protein to creat-
inine ratio, b2-microglobulin to creatinine ratio, fractional
excretion of uric acid, and fractional excretion of phosphate)
(Covance Laboratories, Indianapolis, IN), and measurement
of HIV RNA concentration (Roche TaqMan 2.0; Roche
Diagnostics, Rotkreuz, Switzerland). Participants with con-
firmed virologic failure (2 consecutive viral load samples
.50 c/mL) and an HIV RNA .400 c/mL at week 8 or later
had the second, confirmatory, sample sent for resistance
analysis by GeneSeq Integrase, PhenoSense GT, and
PhenoSense Integrase (Monogram Biosciences, South San
Francisco, CA). Dual energy x-ray absorptiometry of the hip
and lumbar spine was conducted at baseline and weeks 24,
48, 72, and 96.
The studies were approved by the US FDA and by
institutional review boards at all sites.
Statistical Analysis
Noninferiority of TAF compared with TDF when each
were combined with E/C/F was assessed by examining the
proportion of participants in each arm with plasma HIV-1
RNA less than 50 copies per milliliter at week 96 as defined
by the US FDA snapshot algorithm. An inferiority margin of
12% was prespecified with a 2-sided 95% CI (alpha level
was not adjusted). Adverse events were coded with the
Medical Dictionary for Regulatory Activities (version 18.0).
We used Fisher exact test to compare treatment differences
for adverse events and Wilcoxon rank-sum test to compare
treatment differences for continuous laboratory test results
(SAS, version 9.2; SAS Institute, Cary, NC).
RESULTS
Of the 2175 participants screened for both studies, 1744
were randomized and 1733 received at least one dose of study
drug: 866 received TAF and 867 received TDF (see Table S1,
Supplemental Digital Content, http://links.lww.com/QAI/A785
for baseline characteristics). There were high rates of retention
through week 96 (TAF 89% versus TDF 87%). Baseline
characteristics, as previously reported, were similar between
treatment groups; 15% were female and 25% identified
themselves as Black or of African descent. The median (Q1,
Q3) baseline HIV-1 RNA was 4.58 (4.14, 4.96) log10 copies
per milliliter, 17.4% had .100,000 to #400,000 copies per
milliliter, and 5.2% had .400,000 copies per milliliter. At
baseline, 2.9% had a CD4 cell count ,50 cells per microliter,
10.3% had 50 to ,200 cells per microliter, and 31.5% had
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.500 cells per microliter. The median (Q1, Q3) values for
estimated creatinine clearance (Cockcroft–Gault) at baseline
were 115.6 mL/min (99.5, 134.4). Eleven percent of partic-
ipants had a medical history of hyperlipidemia (n = 195).
At 96 weeks, 86.6% in the TAF arm and 85.2% in the
TDF arm had HIV-1 RNA ,50 c/mL (difference 1.5%; 95%
CI [21.8%, 4.8%]), (Fig. 1). By 96 weeks, virologic failure
with resistance occurred in 18 participants: 10 of 866 (1.2%)
in the TAF arm versus 8 of 867 (0.9%) participants in the
TDF arm. In the TAF arm, detected resistance mutations
included 6 participants with M184V/I plus EVG resistance
mutations (T66A/I/V, E92Q, Q148R), 2 with only M184V/I,
1 with K65R plus M184V plus EVG resistance mutations
(N155H), and 1 with K65N plus EVG resistance mutation
(N155H). In the TDF arm, detected resistance mutations
included 3 participants with M184V only, 2 with K65R plus
M184V plus EVG resistance mutations (E92Q, Q148R), 1
with M184V plus EVG resistance mutation (E92Q), 1 with
K65N plus EVG resistance mutation (N155H), and 1 with
only EVG resistance mutation (N155S). For all of those with
detected EVG resistance mutations, genotypic susceptibility
to raltegravir was only retained for 3 of 18; genotypic
susceptibility to dolutegravir was either retained or predicted
to be retained by genotypic algorithm. Three participants in
each arm had antiretroviral resistance that was newly detected
between weeks 48 and 96. Across both arms, development of
resistance was associated with higher baseline viral load. In
the subjects with resistance, there was no statistical difference
in baseline viral load between TAF and TDF arms (375,000
versus 105,000, respectively; P = 0.2).
Both regimens continued to be well-tolerated through
week 96 with similar rates of drug-related adverse events in the
TAF (42.4%) and TDF (45.9%) arms (P = 0.15). The most
commonly reported drug-related adverse events in both arms
were nausea, diarrhea, and headache—each occurring in less
than 10% of participants. Adverse events leading to study drug
discontinuation occurred in 10 (1.2%) on TAF versus 20
(2.3%) on TDF (P = 0.096) (see Table S2, Supplemental
Digital Content, http://links.lww.com/QAI/A785 for details).
Serious adverse events were infrequent and similar between
groups (TAF, 11.2% versus TDF, 10.0%). Five (0.6%)
participants in the TAF arm experienced serious adverse events
that were considered drug-related by the investigator including
abdominal pain, staphylococcal skin infection, rotator cuff
syndrome, erythematous rash, and hypovolemic shock. In the
TDF arm, 2 participants (0.2%) experienced serious adverse
events that were considered drug-related by the investigator
including cholelithiasis and immune reconstitution inflamma-
tory syndrome. Likewise, grade 3 or 4 laboratory abnormalities
were similar between the study groups (TAF, 27.6% versus
TDF, 25.1%); the most common of these was elevation of
creatine kinase (TAF, 9.4% versus TDF, 7.3%).
Participants receiving TAF had smaller declines in BMD
at the hip and spine than those receiving TDF at week 48; the
differences between the groups for both hip and spine BMD
increased through week 96 (Fig. 2, Panel A). In the TAF group,
hip BMD declined initially and then stabilized, whereas the
TDF group continued to lose hip BMD. In the TAF group, spine
BMD declined initially, stabilized, and trended toward improve-
ment, whereas in the TDF group, spine BMD declined and
stabilized. Fractures were rare in both treatment arms 3 (0.3%)
in the TAF group and 9 (1.0%) in the TDF group (P = 0.14),
and were reported to be due to trauma and unrelated to the study
drug. After week 48, 3 male TDF participants (aged 20, 37, and
50) discontinued study medication because of a greater than 5%
decrease in BMD as compared with no discontinuations due to
BMD decreases in the TAF arm. Through 96 weeks, use of
medications to improve bone density (mostly calcium and
vitamin D supplementation) was reported by 15% of those in the
TAF arm and 18% of those in the TDF arm (P = 0.057).
Through 96 weeks, the median change from baseline in
estimated creatinine clearance was significantly lower with
TAF than TDF (22.0 mL/min versus 27.5 mL/min, respec-
tively, P # 0.001). Significantly fewer participants in the TAF
group (15.0%) had a $25% decrease from baseline in
estimated creatinine clearance compared with the TDF group
(30.2%) (P # 0.001). Quantitative markers of proteinuria
(urine protein/Cr), albuminuria (UA/Cr) (Fig. 2, Panel B), and
specific markers of proximal tubular proteinuria (retinol-
binding protein/Cr and b-2-microglobulin/Cr) increased sig-
nificantly in the TDF group, whereas significant declines or
smaller increases were observed in the TAF group (P , 0.001
for all) (Fig. 2, Panel C). There were fewer participants in the
TAF group with clinically significant proteinuria defined as
UPCR .200 mg/g (n = 27 versus 42, P = 0.030) or clinically
significant albuminuria (n = 37 versus 54, P = 0.001).
There were no discontinuations of study drug because
of renal events in the TAF group, whereas there were 6
FIGURE 1. Viral Efficacy at Week 96
(FDA snapshot).
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participants who discontinued TDF because of renal adverse
events (P = 0.03): 4 before week 48 and 2 after week 48
including one due to elevated creatinine and another due to
proximal tubulopathy (reported by the site investigator as
Fanconi syndrome/glycosuria). There have been no cases of
proximal tubulopathy reported in the TAF group. In the TDF
group, in addition to the discontinued participant noted
above, another participant with tubular disorder has been
reported and remains on study drug at the discretion of the
site investigator.
Increases from baseline in total, LDL, and HDL
cholesterol as well as triglycerides all were significantly
greater in the TAF than TDF arm (P , 0.001 for all
comparisons) (see Table S3, Supplemental Digital Content,
http://links.lww.com/QAI/A785 for details). There were no
differences between TAF and TDF in cardiovascular events:
FIGURE 2. Week 96 Bone and Renal
Outcomes. A, change in Spine and
Hip Bone Mineral Density (BMD). B,
change in Quantitativel Proteinuria.
C, change in Tubular Proteinuria
(RBP/Cr and b2-M/Cr).
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2.4% versus 3.1% (P = 0.46), serious cardiovascular events:
0.6% versus 0.5% (P = 0.75), or rate of initiation of lipid-
modifying agents: 3.8% versus 4.4% (P = 0.63).
DISCUSSION
After 2 years, the single-tablet regimen that combined
TAF with E/C/F produced a rate of virologic suppression
in treatment-naive participants that was high (87%)
and remained noninferior to TDF. Concordant with this
durably, high level of suppression of viral replication is the
rare emergence of antiretroviral resistance in the 2 arms
combined above, detected in only 1% (n = 18) of the
1733 participants.
During this extended period of study, both study regimens
were well tolerated with few participants discontinuing therapy
due to adverse events: 1.2% on TAF versus 2.3% on TDF.
However, as seen at week 48, TAF continued to demonstrate
a better bone and renal safety profile than TDF.14 Despite
a trend toward a greater use of agents to increase bone density
in the TDF arm, the differences between TAF and TDF in
BMD observed at week 48 widened by week 96, and spine
BMD was observed to improve toward baseline levels during
this period in those on TAF, while remaining decreased and
largely unchanged in those on TDF. Similarly, markers of
renal function persisted in being more favorable among those
assigned to TAF. A small and rapid decline in estimated
creatinine clearance is expected with administration of
cobicistat, which is known to interfere with the tubular
secretion of creatinine without affecting renal function. A
characteristic decline in estimated creatinine clearance was
observed in both study arms but was more profound in those
in the TDF arm as demonstrated by the significant difference
favoring TAF in the percent who had an estimated creatinine
clearance decline of .25%. Tubulopathy, a rare toxicity of
TDF, was reported in 2 participants receiving this agent,
whereas it was not seen in any participant in the TAF arm.
Together, these longer-term safety data support the hypoth-
esis that circulating levels of TFV are responsible for the bone
and renal toxicity of TDF and that the markedly reduced TFV
level delivered by TAF minimizes such exposure and is
protective against renal and bone effects.
Overall, in these large, international, randomized trials,
at 96 weeks, 87% of those assigned to TAF combined with E/
C/F were virologically suppressed; TAF remained noninferior
to TDF in virologic efficacy and produced significantly more
favorable changes in multiple markers of renal and bone
health. These longer-term data support the use of TAF with E/
C/F/as a safe, well-tolerated, and durable regimen for initial
and ongoing HIV-1 treatment.
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